- Report
- September 2025
- 100 Pages
Global
From €4442EUR$4,900USD£3,784GBP
- Report
- May 2026
- 180 Pages
Global
From €4079EUR$4,500USD£3,475GBP
- Report
- April 2026
- 150 Pages
Global
From €3621EUR$3,995USD£3,085GBP
- Report
- May 2026
- 292 Pages
Global
From €4487EUR$4,950USD£3,823GBP
- Report
- January 2026
- 195 Pages
Global
From €3213EUR$3,545USD£2,738GBP
€3571EUR$3,939USD£3,042GBP
- Report
- October 2025
Global
From €4442EUR$4,900USD£3,784GBP
- Report
- September 2025
- 100 Pages
Global
From €4442EUR$4,900USD£3,784GBP
- Report
- May 2026
- 136 Pages
Global
From €2718EUR$2,999USD£2,316GBP
€3625EUR$3,999USD£3,088GBP
- Report
- April 2026
- 147 Pages
Global
From €2718EUR$2,999USD£2,316GBP
€3625EUR$3,999USD£3,088GBP
- Report
- February 2026
- 250 Pages
Global
From €4070EUR$4,490USD£3,468GBP
- Report
- July 2026
- 476 Pages
Global
From €5303EUR$5,850USD£4,518GBP
- Report
- June 2026
- 185 Pages
Global
From €3213EUR$3,545USD£2,738GBP
€3571EUR$3,939USD£3,042GBP
- Report
- January 2026
- 180 Pages
Global
From €3213EUR$3,545USD£2,738GBP
€3571EUR$3,939USD£3,042GBP
- Report
- January 2026
- 190 Pages
Global
From €3213EUR$3,545USD£2,738GBP
€3571EUR$3,939USD£3,042GBP
- Report
- August 2025
- 197 Pages
Global
From €3213EUR$3,545USD£2,738GBP
€3571EUR$3,939USD£3,042GBP
- Report
- May 2026
- 180 Pages
Global
From €4079EUR$4,500USD£3,475GBP
- Report
- January 2026
- 185 Pages
Global
From €4079EUR$4,500USD£3,475GBP
- Report
- May 2026
- 185 Pages
Global
From €4079EUR$4,500USD£3,475GBP
- Report
- February 2026
- 250 Pages
Global
From €4070EUR$4,490USD£3,468GBP
- Report
- February 2026
- 250 Pages
Global
From €4070EUR$4,490USD£3,468GBP

Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing.
The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place.
Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more